PLEASANTON, Calif. (AP) — PLEASANTON, Calif. (AP) — 10x Genomics Inc. (TXG) on Wednesday reported a loss of $49 million in its fourth quarter. The Pleasanton, California-based company said it had a ...

Barclays lowered the firm’s price target on 10x Genomics to $18 from $19 and keeps an Overweight rating on the shares. The firm expects the life science tools and diagnostics group to be down ...

In this article, we are going to take a look at where 10x Genomics, Inc. (NASDAQ ... applications and spark unfathomable changes in human-computer interaction. Narrowing it down to specific ...

CZI is embarking on this landmark initiative in collaboration with partners 10x Genomics, Ultima Genomics ... of the fundamental biology underpinning human health and disease while supercharging ...

The market expects 10x Genomics (TXG) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus ...

10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...

Coupled with the invalidation of 10x Genomics’ 10,155,981 patent last year ... Parse Biosciences is a global life sciences company whose mission is to accelerate progress in human health and ...

20:39 EST Cathie Wood’s ARK Investment buys 77.6K shares of 10x Genomics (TXG) today Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and ...

"This is a win for the research community," the company's the CEO says. The lawsuit against the company was filed in August 2022. Seattle-based Parse Biosciences secured another major legal ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...